Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

April 27, 2021

Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

Amsterdam, April 27, 2021 – Modra Pharmaceuticals (“Modra”) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board. The new members bring more than 50 years of combined experience in the pharmaceutical and biotechnology industry, and will provide guidance critical for the acceleration of Modra’s growth and business development efforts, as well as the company’s plans for the advancement of lead clinical candidate, ModraDoc006/r, a boosted oral formulation of docetaxel. Modra recently presented preliminary data from its Phase IIb trial of ModraDoc006/r, which showed a positive safety and tolerability profile in metastatic castrate resistant prostate cancer.

“Hemanshu and Klaus are fantastic additions to Modra’s Supervisory Board as we move into late-stage clinical development with ModraDoc006/r and execute the next stage of our growth as a company. Their experience in medical affairs, corporate development, as well as clinical and commercial development, will be an invaluable asset to us. I am delighted to welcome both of them, and look forward to their insights as we continue to advance our lead program towards pivotal studies as a convenient and better tolerated oral taxane therapy for prostate and breast cancer,” commented Colin Freund, CEO of Modra.

Dr. Shah has over thirty years’ experience in both large pharmaceutical and emerging biotechnology companies including BMS, Astellas, Innate and Johnson & Johnson. His experience encompasses multiple functional areas including drug development, strategic marketing, business development and commercial operations with a focus in oncology. He has a PhD in Pharmaceutical Sciences from Rutgers University and an MBA from the University at Buffalo. 

Dr. Schollmeier is an advisor, board member and chairman of several biotech companies and mentors a number of start-ups across Europe. He was CEO of SuppreMol before it was sold to Baxalta. Prior to that, he served as CEO and Chairman of the Board of Santhera. He also served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Mr. Schollmeier holds a PhD in biology from the University of Düsseldorf.

Full biographies for all supervisory board members are also available on the Modra Website

About Modra Pharmaceuticals

Modra Pharmaceuticals aims to transform taxane therapy by developing therapies that are less toxic, more effective and can be taken at home in tablet form. The Company’s goal is to dramatically improve the therapeutic outcomes and everyday lives of the hundreds of thousands of cancer patients undergoing taxane therapy worldwide. Modra’s lead program is nearing completion of a randomized Phase 2b clinical study in prostate cancer to further demonstrate the value of the approach, having already shown promising results in earlier studies in prostate and breast cancers.

Contacts
Colin Freund

CEO, Modra Pharmaceuticals

colin.freund@modrapharmaceuticals.com

Tel: +1 609 933 8008

Trophic Communications

Gretchen Schweitzer or Valeria Fisher

modra@trophic.eu

Tel: +49 (0) 89 2388 7735 or +49 (0) 175 804 1816

Home > News > Modra Pharmaceuticals Appoints Two New Supervis...

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds